看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。9 k% ^0 o& Z4 B5 ]% T
' I$ f1 ?6 r% l6 F9 ]/ d, q7 C- V$ p! `
Currently available feasibility data for possible combination strategies. * r, g* M8 t$ E- X) j1 t
————————————————————————————————
. z: C! m( |- h& RCombination Feasibility according to preliminary data
3 C6 I4 b; }& Y3 v; [——————————————————————————————————4 i+ |1 i( G9 t" o* N+ Q) i: q: v# l
Bevacizumab + sorafenib Yes, reduced dose & \1 y2 j& M) w2 U0 F% ^$ z+ v
Bevacizumab + sunitinib† No , ]4 R5 {, Z& b
Bevacizumab + temsirolimus Yes
1 h- V9 n; ]9 s' VBevacizumab + everolimus Yes
3 V. a( l6 L8 r$ Z3 _& |9 X5 gSorafenib + sunitinib ? # o" |1 M- e8 i
Sorafenib + temsirolimus Yes, reduced dose # `) u v% }9 O7 T- _/ B
Sorafenib + everolimus Yes, reduced dose . u' D9 N# b2 ]; _
Sunitinib + temsirolimus† No
% E" ]: r& G4 i9 d# M, l1 _3 e7 NSunitinib + everolimus ?
* S4 U6 {! O- c7 x. g+ bTemsirolimus + everolimus ?
8 d6 }& N/ b8 F0 E. F————————————————————2 L' m; D" y6 S7 f# n
†Led to US FDA warning.
7 c5 q9 |+ K; b6 b4 a: P?: As yet unattempted combination.
6 P# Z1 Z# T# i+ y) `3 e3 k" Q |
显身卡
8 X/ |% N% c! q9 M7 \# h. ~
